Patterns and correlates of PrEP drug detection among MSM and transgender women in the global iPrEx study

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue 5, 2014, Pages 528-537

  Liu, Albert ^a,b   Glidden, David V ^b   Anderson, Peter L ^c   Amico, K Rivet ^d   McMahan, Vanessa ^e   Mehrotra, Megha ^e   Lama, Javier R ^f   MacRae, John ^g   Hinojosa, Juan Carlos ^h   Montoya, Orlando ⁱ   Veloso, Valdilea G ^j   Schechter, Mauro ^a   Kallas, Esper G ^k   Chariyalerstak, Suwat ^l,m   Bekker, Linda Gail ⁿ   Mayer, Kenneth ^o   Buchbinder, Susan ^a,b   Grant, Robert ^b,e  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e GLADSTONE INSTITUTES   (United States)

^f ASOCIACIÓN CIVIL IMPACTA SALUD Y EDUCACIÓN   (Peru)

^g Investigaciones Medicas en Salud   (Peru)

^h ASOCIACIÓN CIVIL SELVA AMAZÓNICA   (Peru)

ⁱ Fundacion Ecuatoriana Equidad   (Ecuador)

^j Funda??o Oswaldo Cruz   (Brazil)

^k UNIVERSITY OF SÃO PAULO   (Brazil)

^l CHIANG MAI UNIVERSITY   (Thailand)

^m Faculty of Medicine Chiang Mai University   (Thailand)

ⁿ UNIVERSITY OF CAPE TOWN   (South Africa)

^o HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

Adherence; Drug detection; Emtricitabine tenofovir; Men who have sex with men; Pre exposure prophylaxis

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ANTIRETROVIRUS AGENT;

AGE; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; DRUG DETERMINATION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; PHASE 3 CLINICAL TRIAL (TOPIC); PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSGENDER; ADOLESCENT; ADULT; BLOOD ANALYSIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG UTILIZATION; HIV INFECTIONS; MALE HOMOSEXUALITY; MEDICATION COMPLIANCE; MIDDLE AGED; PREVENTION AND CONTROL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; BLOOD CHEMICAL ANALYSIS; CHEMOPREVENTION; DISEASE TRANSMISSION, INFECTIOUS; DRUG UTILIZATION; FEMALE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRE-EXPOSURE PROPHYLAXIS; TRANSGENDERED PERSONS; UNITED STATES; YOUNG ADULT;

EID: 84925555523     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000351     Document Type: Article

References (36)

1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410.
2. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preex-posure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-434.
3. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083-2090.
4. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-2599.
5. Hendrix CW. Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design. Cell. 2013;155:515-518.
6. Koenig LJ, Lyles C, Smith DK. Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: lessons learned from trials and treatment studies. Am J Prev Med. 2013;44(1 suppl 2):S91-S98.
7. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4:151ra125.
8. Karim SS, Kashuba AD, Werner L, et al. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011;378:279-281.
9. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
10. Marrazzo J, Ramjee G, Nair G. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). Paper presented at: Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013;Atlanta, GA.
11. Williams AB, Amico KR, Bova C, et al. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013;17:284-287.
12. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(suppl 1):S79-S87.
13. Muchomba FM, Gearing RE, Simoni JM, et al. State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr. 2012;61:490-498.
14. Delahunty T, Bushman L, Robbins B, et al. The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:1907-1914.
15. Bushman LR, Kiser JJ, Rower JE, et al. Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal. 2011;56:390-401.
16. Agresti A. An Introduction to Categorical Data Analysis. 2 ed. Hoboken, NJ: John Wiley & Sons, Inc; 2007.
17. Gilmore H, Liu A, Koester K, et al. Participant experiences and facilitators and barriers to pill-use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco, United States. AIDS Patient Care STDS. 2013;27:560-566.
18. Goicochea P, Lama J, Vargas L. Barriers and facilitators to PrEP adherence in iPrEx: a prevention trial that started in 3 Andean cities. 15th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009; Y162.
19. Nachega JB, Hislop M, Nguyen H, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr. 2009;51:65-71.
20. Clare C, Fraser C. Contraception adherence among East Harlem adolescents. Gynecol Obstet. 2013;3.
21. Pilote L, Tulsky JP, Zolopa AR, et al. Tuberculosis prophylaxis in the homeless. A trial to improve adherence to referral. Arch Intern Med. 1996;22:161-165.
22. Hyre AD, Krousel-Wood MA, Muntner P, et al. Prevalence and predictors of poor antihypertensive medication adherence in an urban health clinic setting. J Clin Hypertens (Greenwich). 2007;3:179-186.
23. Naderi S, Bestwick J, Wald D. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125:882-887.
24. Lewey J, Shrank WH, Bowry AD, et al. Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J. 2013;165:665-678, 678.e661.
25. Haberer JE, Baeten JM, Campbell J, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10:e1001511.
26. Balaji AB, Bowles KE, Le BC, et al. High HIV incidence and prevalence and associated factors among young MSM, 2008. AIDS. 2013;27:269-278.
27. Beyrer C, Sullivan P, Sanchez J, et al. The increase in global HIV epidemics in MSM. AIDS. 2013;27:2665-2678.
28. Wheelock A, Eisingerich AB, Ananworanich J, et al. Are Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptance. PLoS One. 2013;8:e54288.
29. Gallagher T, Link L, Ramos M, et al. Self-perception of HIV risk and candidacy for pre-exposure prophylaxis among men who have sex with men testing for HIV at commercial sex venues in New York City. J LGBT Health Res. 2014;1:218-224.
30. Hosek SG, Siberry G, Bell M, et al. The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr. 2013;62:447-456.
31. Blaschke TF, Osterberg L, Vrijens B, et al. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012;52:275-301.
32. Blum MR, Chittick GE, Begley JA, et al. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol. 2007;47:751-759.
33. Hawkins T, Veikley W, St Claire RL III, et al. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr. 2005;39:406-411.
34. Dai JY, Gilbert PB, Hughes JP, et al. Estimating the efficacy of preexposure prophylaxis for HIV prevention among participants with a threshold level of drug concentration. Am J Epidemiol. 2013;177:256-263.
35. Castillo-Mancilla JR, Zheng JH, Rower JE, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013;29:384-390.
36. Liu A, Yang Q, Huang Y, et al. Strong relationship between oral dose and tenofovir hair levins in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One. 2014;9:e83736.